Psychedelic drops depression scores 19.5 points, placebo 11.9.

Helus Pharma reported the Phase 3 results Monday, and a number of serious adverse events raise safety questions.

At 12 weeks the gap held: 16.9 points against 9.9 on placebo, with patients also on standard antidepressants.

The company announced the results itself, and no peer-reviewed paper has yet confirmed them.

How each outlet framed it
STAT
leads with the Phase 3 efficacy numbers (MADRS -19.5 vs -11.9 at six weeks) before the serious adverse events, reversing the safety-first framing

Sources: STAT